Several hedge funds and other institutional investors have recently added to or reduced their stakes in SRNE. Cormorant Asset Management LP grew its holdings in shares of Sorrento Therapeutics by 25.0% during the 1st quarter. Cormorant Asset Management LP now owns 5,000,000 shares of the biopharmaceutical company’s stock worth $9,200,000 after purchasing an additional 1,000,000 shares during the period. Alliancebernstein L.P. lifted its stake in Sorrento Therapeutics by 146.3% during the 1st quarter. Alliancebernstein L.P. now owns 673,400 shares of the biopharmaceutical company’s stock worth $1,239,000 after acquiring an additional 400,000 shares in the last quarter. Swiss National Bank acquired a new position in Sorrento Therapeutics during the 2nd quarter worth about $1,653,000. JPMorgan Chase & Co. lifted its stake in Sorrento Therapeutics by 584.4% during the 1st quarter. JPMorgan Chase & Co. now owns 280,747 shares of the biopharmaceutical company’s stock worth $517,000 after acquiring an additional 239,729 shares in the last quarter. Finally, Raymond James & Associates lifted its stake in Sorrento Therapeutics by 1,960.7% during the 2nd quarter. Raymond James & Associates now owns 231,829 shares of the biopharmaceutical company’s stock worth $1,456,000 after acquiring an additional 220,579 shares in the last quarter. Institutional investors and hedge funds own 16.14% of the company’s stock.
The Olympia Report
